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Abstract
Short-chain fatty acids (SCFAs) are increasingly being monitored to elucidate the link between gut health and disease. These
metabolites are routinely measured in faeces, but their determination in serum is more challenging due to their low concentrations. A method for the determination of eight SCFAs in serum is described here. High-resolution mass spectrometry and gas
chromatography were used to identify the presence of isomeric interferences, which were then overcome through a combination
of chromatographic separation and judicious choice of MS fragment ion. The SCFAs were derivatised to form 3nitrophenylhydrazones before being separated on a reversed-phase column and then detected using liquid chromatography
tandem mass spectrometry (LC-QQQ-MS). The LODs and LOQs of SCFAs using this method were in the range 1 to
7 ng mL−1 and 3 to 19 ng mL−1, respectively. The recovery of the SCFAs in serum ranged from 94 to 114% over the three
concentration ranges tested.
Keywords SCFA . High-resolution mass spectrometry . LC-MS/MS . Serum

Introduction
Short-chain fatty acids (SCFAs) are the end products of fermentation of dietary fibre by anaerobic intestinal microbiota. As
humans lack the enzymes to degrade the bulk of dietary fibres,
nondigestible carbohydrates pass the upper gastrointestinal tract
unaffected and are fermented in the caecum and the large intestine by the anaerobic caecal and colonic microbiota.
Fermentation results in multiple groups of metabolites including
the SCFAs [1]. SCFAs are saturated aliphatic organic acids that
consist of one to six carbons of which acetic acid (C2), propionic
acid (C3), and butyric acid (C4) are the most abundant (95%).
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The SCFAs produced in the caecum/large intestine are
absorbed in the colon and either utilised in colonocytes or
transported via the portal vein to reach the blood circulation
and other organs. Transported SCFAs act as substrates or signal molecules that provide a link between the diet, the microbiota, and the host, and mediate health benefits locally in the
gut and at the systemic level [2]. The amount and type of fibre
consumed have dramatic effects on the composition of the
intestinal microbiota and consequently on the type and
amount of SCFAs produced.
In humans, the effect of dietary fibre intake has been studied by measuring the SCFA concentrations in faeces and calculating the total rate of SCFA excretion. Higher concentrations of SCFAs in faeces have been positively associated with
a higher dietary intake of fibre [3]. However, faecal SCFA
concentrations do not reflect the concentration and production
rate of SCFAs in the intestine or the level of absorption of
SCFAs by the host. The distinct relationship between the level
of faecal SCFAs, the composition, and the ratio of the
intestinal microbiota and health is unclear [4]. To gain
more understanding of the link between nutritional disorders, gut microbiota, and gut microbiota–derived metabolites, it is important to accurately measure both
circulating/blood and faecal SCFAs.

6334

SCFA concentrations in the colon and faeces are relatively
easy to quantify as intestinal concentrations are in the millimolar
range. However, SCFA concentrations in plasma and serum are
considerably lower and range between 50 and 100 μmol L−1 for
acetate and 0.5–10 μmol L−1 for propionate and butyrate [5].
Thus, the measurement of SCFAs in serum at these concentrations
is more complicated and prone to interferences.
Traditionally, gas chromatography (GC) is the technique of
choice for the analysis of SCFAs [5–8]. However, recently, several
LC-MS methods have been reported for the analysis of SCFAs [5,
9–13]. The SCFAs are typically derivatised as the low molecular
weight of the native SCFAs makes them susceptible to interference when using MS detection, and also results in low recovery
due to their volatility. Derivatisation has the added advantage of
reducing the polarity of the SCFAs and making them more amenable to retention on a reversed-phase column.
Han et al. (2015) reported a novel derivatisation reagent, 3nitrophenylhydrazine (3-NPH), for the sensitive detection of
SCFAs by LC-MS. The method was fully validated, and the
authors reported good sensitivity and importantly excellent
chemical stability of the derivatives [9]. As greater detection
sensitivity is required for serum and plasma samples compared to faecal samples, Zeng and Cao (2018) investigated
several derivatisation reagents to determine which one provided maximum analyte sensitivity and optimal separation of the
SCFAs and ketone bodies in mouse serum from interfering
structural isomers [10]. While they recommended the use of obenzylhydroxylamine (O-BHA) as a derivatising reagent for
the simultaneous determination of SCFAs and ketone bodies,
they did report superior sensitivity for the SCFAs when
derivatised with 3-NPH compared to O-BHA. Song et al.
(2019) also used LC-MS to monitor the concentrations of
SCFAs in mouse plasma but used 4-acetamido-7-mercapto2,1,3-benzoxadiazole as the derivatising reagent. While the
derivatisation method had the advantage of being completed
at room temperature, the excessive chromatographic run time
of 65 min for baseline resolution of the isomeric structures
was a serious limitation [13]. Therefore, in this work, we
chose to use 3-NPH to convert SCFAs to their 3nitrophenylhydrazones under optimised conditions for their
accurate quantification in human serum using LC-MS/MS.
Additionally, we report the use of GC and LC both coupled
to a high-resolution mass spectrometry as orthogonal methods
that use fundamentally different principles (detection or separation) to inform the development of an LC-MS/MS method.
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acid-D 7 was purchased from Cambridge Isotope
Laboratories (Cambridge, MA, USA). Acetic acid, propionic
acid, isobutyric acid, butyric acid, isovaleric acid, valeric acid,
4-methyl valeric acid, hexanoic acid, 13C2-acetic acid, 2ethylbutyric acid, methyl tert-butyl ether (MTBE), 3nitrophenylhydrazine hydrochloride (3-NPH.HCl), 1-ethyl3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDC.HCl), and pyridine were all purchased from SigmaAldrich (Sydney, Australia).

Preparation standards
Stock solutions of acetic acid, propionic acid, isobutyric acid,
butyric acid, isovaleric acid, valeric acid, 4-methylvaleric acid, and hexanoic acid were prepared in 20% methanol/water at
concentrations of 10.5, 7.425, 1.455, 1.455, 9.6, 2.775, 2.769,
and 2.79 mg mL−1, respectively. Mixed calibration standard
solutions (eight) in the range 0.015–1 μg mL−1 for valeric
acid, 4-methylvaleric acid, and hexanoic acid; 0.0375–
2.5 μg mL−1 for propionic acid, isobutyric acid, and butyric
acid; 0.15–10 μg mL−1 for isovaleric acid; and 0.375–
25 μg mL−1 for acetic acid were prepared in water. Three
QC standards at 0.015, 0.1, and 1 μg mL−1 for valeric acid,
4-methylvaleric acid, and hexanoic acid; 0.0375, 0.25, and
2.5 μg mL−1 for propionic acid, isobutyric acid, and butyric
acid; 0.15, 1, and 10 μg mL−1 for isovaleric acid; and 0.375,
2.5, and 25 μg mL−1 for acetic acid were also prepared in
water.
The internal standards were prepared in water at a concentration of 1 mg mL−1. Aliquots (2 mL) were stored at − 80 °C.
An internal standard solution containing the labelled internal
standards (13C2-acetic acid (35 μg mL−1), D7-butyric acid
(3.84 μg mL−1), and 2-ethyl butyric acid (1 μg mL−1)) were
prepared in LC-MS-grade acetonitrile.

Serum samples
Briefly, venous blood samples were obtained from healthy
volunteers from the antecubital vein and collected in SST
vacutainer tubes (Becton Dickinson, NJ, USA). Serum samples were allowed to clot for at least 30 min at room temperature, before subsequently being centrifuged at 1300g for
15 min. The supernatant was then immediately aliquoted
and stored at − 80 °C.

Sample preparation for LC-MS analysis

Materials and methods
Chemicals and reagents
LC-MS-grade water and acetonitrile (ACN) were purchased
from Thermo Fisher Scientific (Sydney, Australia). Butyric

Serum was thawed and 200 μL was transferred to a 15-mL
polypropylene centrifuge tube. The ACN solution containing
internal standards (600 μL) was added to the thawed serum
samples, and the samples were allowed to sit on ice for
20 min. The ACN layer was separated by centrifuging the
samples at 4 °C (300g × 2 min) and transferred to a separate
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15-mL centrifuge tube, and 200 μL water was added to the
solution. The SCFAs were derivatised to alkyl hydrazones by
adding 600 μL of 200 mM 3-nitrophenylhydrazine hydrochloride (3-NPH-HCL) solution in 50% acetonitrile/water
and 600 μL of 120 mM 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC.HCl) containing 6% pyridine solution in 50% acetonitrile/water. The samples were
heated at 40 °C on a Reacti-block (Hangzhou Ruicheng,
China) for 30 min and then placed immediately on ice. The
SCFAs were then extracted with two sequential aliquots of
MTBE (5.0 mL and 4.0 mL). On each addition of MTBE,
the solution was gently mixed and then centrifuged at 4 °C
at (300g × 2 min). The combined MTBE extracts were dried
under nitrogen at room temperature, reconstituted with
200 μL of 10% acetonitrile/water, and filtered through 3kDa cut-off filters.
Calibration standards, QC standards, and extraction blanks
(water replaced the serum) were prepared using the same procedure as for the experimental samples.

Sample preparation for GC-HRAM-MS analysis
Serum samples were thawed and 200 μL of each sample was
transferred to separate 15-mL polypropylene tubes and stored
on ice. Ultra-high-purity water (200 μL) was used for a blank
sample. Internal standards were added to the samples: 57 μL
of 13C2-acetic acid solution (35 μg mL−1); 83 μL butyric acidD 7 (3.84 μg/mL); and 63 μL 2-ethylbutyric acid
(0.8 μg mL−1) and mixed well. The samples were then deproteinated by adding 50 μL of a 10% (w/w) sulfosalicylic
acid solution prepared in water. The samples were then
capped and left on ice for 20 min to cool and minimise possible losses of the released volatile SCFAs.
The SCFAs were extracted from the de-proteinated serum
samples with 3.0 mL cold MTBE (refrigerated at 4 °C). The
samples were vortexed and then centrifuged (300g × 2 min) to
separate the layers. The MTBE layer was transferred to a clean
tube containing 50 μL of cold 0.2 M aqueous sodium hydroxide solution to back extract the SCFAs into the aqueous layer.
After vortexing and centrifuging, the MTBE layer was
discarded. Cold phosphoric acid solution (30 μL, 1.0 M)
was then added to the samples and vortexed to mix. The samples were transferred to cold 2 mL GC vials fitted with 200-μL
tapered glass inserts. The samples were diluted 1:5 or 1:8 with
cold high-purity water prior to analysis by GC–high-resolution accurate-mass (HRAM)–MS (GC-HRAM-MS).

LC-HRAM-MS analysis
A Thermo Scientific Ultimate 3000 Liquid Chromatography
coupled to a Thermo Scientific Q Exactive Focus Orbitrap
Mass Spectrometer was used to quantify the SCFAs in serum.
The pooled serum samples were separated on a Thermo

6335

Hypersil aQ column and an ACE C18-PFP column, both having dimensions of 100 mm × 2.1 mm ID and packed with
1.7 μm particles. Water (A) and ACN (B) were used for analyte separation. The initial mobile phase conditions were 99%
A and 1% B, held for 2 min. Solvent A was reduced to 90%
over 2 min, and then further reduced to 10% over 1 min and
held for 5 min before returning to initial conditions. The flow
rate was 0.2 mL min−1 and column temperature was maintained at 30 °C.
An ACE C18-AR column (100 mm × 2.1 mm ID; 1.7 μm
particle diameter) was also used to separate the SCFAs using
water (A) and acetonitrile (B)–based mobile phase. Initial
conditions were 80% A, held for 0.5 min. B was increased
to 30% over 6 min and then to 40% over 4.5 min. The mobile
phase was then increased to 95% B over 1.5 min and held for
2 min. The mobile phase was then returned to starting conditions. The column was maintained at 45 °C and the flow rate
0.3 mL min−1. The sample injection volume was 2 μL.
Full-scan, single ion monitoring (SIM) and parallel reaction monitoring (PRM) analyses were performed using a Q
Exactive Focus mass spectrometer. Electrospray ionisation in
the negative ion mode was used with a spray voltage of
2500 V, an auxiliary gas temperature of 350 °C, and a capillary temperature of 350 °C. Full details of the MS settings for
all three modes are provided in the Supplementary
information.

GC-HRAM-MS analysis
A Thermo Fisher Scientific Q Exactive GC-MS instrument
was used to quantify SCFAs in serum extracts. A robotic
arm (Thermo Scientific ™ TriPlus™ RSH autosampler) was
used to inject 1 μL of sample into a split/splitless (SSL) injector at 230 °C using a 1:5 split flow on a Thermo Fisher
Scientific™ TRACE™ 1310 GC. Helium was used as the
carrier gas at a flow rate of 1.0 mL min−1 with chromatographic separation on a Thermo Fisher Scientific TG-WAXMS A
column (30 m length × 0.25 mm inner diameter × 0.25 μm
film thickness column). The initial oven temperature was held
at 50 °C for 30 s, followed by a 30 °C min−1 temperature ramp
to 110 °C. The oven temperature was then ramped at
5 °C min−1 to 135 °C and then at 20 °C min−1 to a final
temperature of 230 °C and held for 2 min. The transfer line
temperature was set to 230 °C. Electron ionisation (EI) at
65 eV (positive polarity) and an emission current of 50 μA
with an ion source temperature of 250 °C were used in all
experiments. A filament delay of 5.0 min was used, and the
mass spectrometer was operated at a resolution of 120,000
(FWHM at m/z 200). Time-scheduled data acquisition for
the SCFAs was performed by 2 experiments: SIM for acetic
acid (5.5 to 7 min) and PRM (7 to 11 min) for the remaining
SCFAs. The ions monitored for SIM analysis and the
precursor-product transitions monitored in PRM in the
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inclusion list are summarised in Table S1. A collision energy
of 10 eV was used for all PRM transitions, and nitrogen was
used as the collision gas. A mass isolation window of 1.0 m/z
was used, and the maximum injection time was set to “auto” in
both SIM and PRM experiments.

LC-QQQ-MS analysis
A Thermo Scientific Ultimate 3000 Liquid Chromatography
coupled to a Thermo Scientific TSQ Quantiva Triple
Quadrupole Mass Spectrometer was used for the validation
study. Detection was performed in negative mode (2500 V),
and the analytes were ionised by electrospray and monitored
in multiple reaction monitoring (MRM) mode. The LC conditions were as described above for the ACE C18-AR column.
The MS conditions were gases (arbitrary units) sheath 50,
auxiliary 10, sweep 1, ion transfer tube temperature 325 °C,
and vaporiser temperature 350 °C. The ion transitions and
collision energies are presented in Table S2.

Method validation

Shafaei A. et al.

The accuracy of the method was evaluated by a recovery
test. In brief, three pooled serum samples (200 μL) were
spiked with 20 μL of mixed standard solutions at low
(LQC), medium (MQC), and high (HQC) levels of 0.058,
0.232, and 0.465 μg mL−1 for hexanoic acid; 0.058, 0.231,
and 0.462 μg/mL for 4-methyl valeric acid; 0.124, 0.495, and
1.238 μg mL −1 for propionic acid; 0.462, 2.308, and
4.615 μg mL −1 for isovaleric acid; 0.058, 0.233, and
0.465 μg/mL for valeric acid; 0.121, 0.485, and 1.213 μg/
mL for isobutyric acid; 0.120, 0.480, and 1.2 μg mL−1 for
butyric acid; and 0.525, 5.250, and 13.125 μg mL−1 for acetic
acid, respectively. The baseline (unspiked) and spiked serum
samples at each concentration were analysed, and the percentage of recovery was calculated according to Eq. (1), where
Cbaseline is the calculated unspiked analyte concentration,
Crecovered is the calculated spiked analyte concentration, and
Cspiked is the absolute concentration of spiked standard added
to the sample.

Relative recovery ¼

C recovered −C baseline
 100%
C spiked

ð1Þ

Method validation was performed on LC-QQQ and in accordance with ICH and IUPAC guidelines [14, 15].

Linearity, limit of detection, and limit of
quantification
Linearity was determined by constructing calibration curves
over the concentration range (0.015–1 μg mL−1 for valeric
acid, 4-methylvaleric acid, and hexanoic acid; 0.0375–
2.5 μg mL−1 for propionic acid, isobutyric acid, and butyric
acid; 0.15–10 μg mL−1 for isovaleric acid; and 0.375–
25 μg mL−1 for acetic acid) using each of the eight prepared
calibration standards (see “Preparation standards”). The limit
of detection (LOD) and limit of quantification (LOQ) of the
method were determined as a signal to noise ratio (S/N) of 3
and 10 of diluted standard solution, respectively.

Precision, trueness, and accuracy
Precision and trueness of the method were determined by an
intra-day and inter-day analysis of the calibration standards.
The calibration standards were injected 6 times per day (intraday) and 1 time per day for 6 consecutive days (inter-day).
The resulting peak area was used to calculate the coefficient of
variation (% CV) and thus precision. The calculated mean
concentration relative to the nominal concentration was used
to reveal trueness (% bias). Moreover, the relative standard
deviation (% RSD) of the obtained retention times for each
analyte for 12 injections was calculated to predict the retention
time repeatability of the method.

Results and discussion
Chromatographic separation of SCFA
Pooled serum samples were derivatised to form 3nitrophenylhydrazones, and first separated on a Thermo
Hypersil aQ column, and analysed using high-resolution
Orbitrap mass spectrometry in three modes: full scan, SIM,
and PRM. For FS and SIM analysis, the precursor ion for each
analyte was used for quantification (Table S1). For PRM analysis, at least two product ions were monitored and the collision energy which gave the optimal signal for these product
ions was experimentally determined and adopted (Table S1).
The concentration of the SCFA in the pooled samples,
separated on the Hypersil aQ column and analysed by
HRAM-MS, was determined using a one-point calibration
using a standard solution with SCFA concentrations that
closely matched the expected concentration in serum and
using labelled and non-labelled internal standards (13C2-acetic
acid, butyric acid-D7, and 2-ethylbutyric acid). There was
good agreement between the three modes for all analytes, with
the exception of propionic acid (Table 1). The agreement between FS and SIM for propionic acid is expected as both
modes monitor the precursor ion. The lower concentration
reported using the PRM mode, when compared to SIM and
FS, suggests there is an isobaric interference with the precursor ion resulting in elevated results for SIM and FS. In PRM
mode, quantification is determined using a fragment ion,
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Table 1 Comparison of different methods (full scan, PRM, and SIM on
LC-HRAM-MS and PRM on GC-HRAM-MS) for analysis of SCFAs in
different pooled serum samples (n = 2). SCFAs were separated on a
Analyte

Acetic acid

ISTD
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Thermo Hypersil aQ column (LC-HRAM-MS) and on a Thermo TGWAX column (GC-HRAM-MS)

Sample LC-HRAM-MS

13

C2-Acetic acid

Pool 1
Pool 2
Pool 1
Propionic acid
Butyric acid-D7
Pool 2
Pool 1
Isobutyric acid
Butyric acid-D7
Pool 2
Pool 1
Butyric acid
Butyric acid-D7
Pool 2
Pool 1
Isovaleric acid
Butyric acid-D7
Pool 2
Valeric acid
2-Ethylbutyric acid Pool 1
Pool 2
4-Methylvaleric acid 2-Ethylbutyric acid Pool 1
Pool 2
Hexanoic acid
2-Ethylbutyric acid Pool 1
Pool 2

GC-HRAM-MS

PRM

FS

SIM

PRM

Concentration SD
(ng mL−1)

Concentration SD
(ng mL−1)

Concentration SD
(ng mL−1)

Concentration SD
(ng mL−1)

14,627
14,933
1271
1200
1761
1717
1387
1479
2766
3274
107
108
15.7
15.7
826

558
14,782
273
14,872
6.9
2060
13.9
1861
9.4
1749
12.8
1695
10.6
1420
25.9
1331
51.4
2874
23.1
3334
1.1
78.2
1.6
91.2
1.3
23.9
1.0
21.6
22.3
826

761

which is monitored at high resolution providing extra selectivity and hence resolution from coeluting background ions.
The chromatographic method using the Hypersil aQ column resolved the SCFAs (Fig. 1). Several isobaric or isomeric
compounds, and specifically those relating to the butyric and
valeric acids, present in the serum samples were also resolved
(Fig. 1). The fragmentation pattern and predicted elemental
composition for these interferences indicated they were likely
isomeric (see Supplementary information for MS/MS fragmentation pattern and elemental composition). A slight shoulder on the acetic acid peak for some of the pooled serum
samples indicated the presence of an unresolved interference.
In PRM mode, different fragment ions were checked to determine if selecting and monitoring an alternative fragment ion
would remove this interference. This approach was not successful, so chromatographic resolution of the interference was
necessary. Several columns were trialled to resolve acetic acid
from the interfering peak. An ACE C18-PFP column with the
same acetonitrile/water gradient program resolved the interference for acetic acid; however, there was loss of resolution
for isovaleric and its interferences. An ACE C18-AR column
with a modified gradient consisting of water and acetonitrile
as mobile phase successfully resolved acetic acid from its
interference, and at the same time maintained resolution of
the interferences for butyric acid and isovaleric acid

9.3

777

31.2 15,110
35.3 15,303
90.8
2218
22.3
2085
49.0
1736
9.3
1716
11.4
1410
16.4
1354
37.2
2656
54.0
3171
1.6
78.7
1.9
89.6
1.8
13.9
0.8
13.2
8.0
800
21.8

790

111
10,064
530
12,344
82.6
1188
52.1
1115
18.1
2161
50.3
2194
31
1787
33.7
1654
23.7
4387
78.5
5144
4.0
124
0.9
115
2.4
23.1
0.0
22.4
131
912
8.6

916

259
1532
58.1
94.3
125
173
137
141
330
952
11.3
17.1
1.9
1.3
32.9
73

(Fig. 2). Having resolved the acetic acid interference,
it was then possible to determine the potential contribution of the interference to the acetic acid peak; it varied
from 0 to 12% depending on the sample.
As gas chromatography has traditionally been used to determine SCFAs, particularly for faecal material, the pooled
serum samples were also separated using GC coupled to a
HRAM-MS which was operated in SIM (acetic acid) or
PRM mode (all other analytes) (Fig. 3). The analytes were
quantified as for LC-HRAM-MS and the data are presented
in Table 1. As an orthogonal method, this GC experiment was
completed to determine if there were significant unresolved
interferences in the LC method. Elevated concentrations of
SCFA in the LC data when compared to the GC data would
suggest unresolved interferences. There was generally good
agreement between the LC-HRAM-MS (PRM mode) and the
GC-HRAM-MS (PRM mode) methods (± 20%), particularly
with respect to the relative concentrations of the SCFAs in a
given sample. However, there was a large discrepancy between the two techniques for isovaleric acid and to a lesser
extent for isobutyric acid, where the GC method reported elevated concentrations when compared to the LC method. This suggested that the interferences visible and
resolved in LC-MS (Fig. 1) are unresolved in GC and
contribute to the analyte signal. No attempt was made
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Fig. 1 Overlay of extracted ion chromatograms of (1) acetic acid, (2)
13
C2-acetic acid, (3) propionic acid, (4) isobutyric acid, (5) butyric acidD7, (6) butyric acid, (7) isovaleric acid, (8) valeric acid, (9) 2-ethyl butyric

acid, (10) 4-methyl valeric acid, and (11) hexanoic acid of a standard mix
and b pooled serum sample both acquired in PRM mode on a Thermo
Hypersil aQ column (* interference)

to resolve the interferences in the GC method as the
aim of this work was to develop an LC-MS method.

The use of high-resolution mass spectrometry and orthogonal methods when developing methods for analytes in

Fig. 2 Overlay of extracted ion chromatograms of (1) acetic acid, (2)
13
C2-acetic acid, (3) propionic acid, (4) isobutyric acid, (5) butyric acidD7, (6) butyric acid, (7) isovaleric acid, (8) valeric acid, (9) 2-ethyl butyric

acid, (10) 4-methyl valeric acid, and (11) hexanoic acid of pooled serum
sample separated on an ACE C18-AR column in PRM (* acetic acid
interference)

Sensitive and quantitative determination of short-chain fatty acids in human serum using liquid...
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Fig. 3 Total ion chromatograms of (1) acetic acid, (2) propionic acid, (3)
isobutyric acid, (4) butyric acid-D7, (5) butyric acid, (6) isovaleric acid,
(7) valeric acid, (8) 2-ethyl butyric acid, (9) 4-methyl valeric acid, and

(10) hexanoic acid in pooled serum sample separated on a Thermo TGWAX column in GC-HRAM-MS

complex matrices such as serum is informative. However, for
routine analysis, tandem mass spectrometry is preferred and
more widely available. The application of this method to a
low-resolution MS instrument, a triple quadrupole, was explored. The SCFA in five pooled samples were quantitatively
determined using an eight-point calibration curve by
both HR-LC-MS in PRM mode and LC-HRAM-MS in

MRM mode after separation on the ACE C18-AR column. A similar quantitative ion was selected for most
SCFAs in PRM and MRM with the exception of
isovaleric acid and valeric acid. The transition
236 ➔ 137 for isovaleric acid showed contribution from
an unresolved interference for some samples (Fig. 4).
Therefore, transition 236 ➔ 152 where the interference

Fig. 4 Extracted ion chromatograms of MRM transitions (236 > 137 and 236 > 152) monitored for (1) isovaleric acid and (2) valeric acid on an ACE
C18-AR column in MRM (* interference)

6340

Shafaei A. et al.

was not detected was used as the quantitative ion for
the tandem mass spectrometry method (Fig. 4).
There was excellent agreement (95–106%) between the
data obtained from PRM (HRAM instrument) and MRM (tandem MS instrument) modes for acetic, propionic, and
isobutyric acids (Table S5). For butyric acid and isovaleric
acid, there was good agreement (94–117%). However, for
the minor SCFAs, valeric acid and 4-methylvaleric acid were
present at lower concentrations, and typically between 10 and
100 ng mL−1, the agreement was less with the percentage
agreement between 75 and 131% (Table S5). This comparison
of HRAM vs tandem MS after separation on the ACE C18AR column was repeated but with 11 individual serum samples, and again, excellent agreement was obtained for the
SCFAs with the exception of 4-methylvaleric acid, where
the agreement was lower at 71–108% due to its presence in
serum at low concentrations (Table 2). The advantage of using
HRAM-MS to inform the development of a robust method on
a more accessible instrument has been demonstrated.
The LC-MS method was just 15 min long comparing
favourably with other published methods: Song et al. (2019)
separated the SCFAs in 35 min [13], while Wei et al. (2020)
reported a run time of 14 min [11] and Zeng et al. (2018)
reported a run time of just 6 min [10]. The stability of the
SCFA-3-NPH derivatives was previously established by
Han et al. (2015) and was therefore not investigated here [9].

Tandem MS method validation
Linearity, LOD, and LOQ
An eight-point calibration curve was plotted for each analyte
using the ratio of the peak area of the analyte/peak area of IS
versus the ratio of the concentration of the analyte/concentration
of IS. Good linearity was obtained for all analytes over the evaluated concentration range (0.015–1 μg mL−1 for valeric acid, 4-

methylvaleric acid, and hexanoic acid; 0.0375–2.5 μg mL−1 for
propionic acid, isobutyric acid, and butyric acid; 0.15–10 μg/mL
for isovaleric acid; and 0.375–25 μg mL−1 for acetic acid) with
correlation coefficients greater than r2 = 0.999 for all analytes.
The limits of detection (LODs) and limits of quantitation
(LOQs) of the method were calculated (Table S3). The concentration range for each of the SCFA in the serum samples tested
varied quite widely—often as much as 100-fold. For example,
the ranges reported in the 11 serum samples tested for isobutyric
acid and isovaleric acid were 90–1241 ng mL−1 and 23–
3992 ng mL−1 respectively. However, the LOQ of the method
for these analytes (3 and 7 ng mL−1 for isobutyric acid and
isovaleric acid respectively) was sufficient and below the lowest
concentration reported. The LOQ for the method was lower than
the concentration detected for all analytes and all serum samples
(pooled and non-pooled) with one exception—one serum sample
reported a concentration for 4-methylvaleric below its LOQ but
above its LOD. Han et al. (2015) measured the 3-NPH derivatives of the SCFAs in faeces, so this work demonstrates that the
derivatising reagent is also sensitive enough for serum applications, where the concentrations of the SCFAs are several orders
of magnitude lower [9]. Song et al. (2019) selected 4-acetamido7-mercapto-2,1,3-benzoxadiazole as the derivatising reagent to
monitor SCFAs in mouse serum, but with LOQs typically 3–10
times higher than reported here, minor SCFAs such as valeric
and isovaleric acid would not be quantifiable in human serum
[13]. Wei et al. (2020) quantified the SCFAs in mouse serum
after derivatisation with d0/d6-N, N-dimethyl-6,7-dihydro-5Hpyrrolo [3,4-d] pyrimidine-2-amine using HRAM-MS operating
in PRM mode and reported LOQs in the range 0.5–4 fg on
column (for a 10-μL sample injection) [11]. Our LOQs based
on a similar injection volume compare favourable ranging from 1 to 5 fg on column. Zhang et al. (2020)
recently reported a GC-MS method where the SCFAs
extracted from mice serum were derivatised with
BSTFA to improve sensitivity and reported LOQs in

Table 2 Comparison of MRM mode in LC-QQQ and PRM mode in LC-HRAM-MS for quantitative analysis of SCFAs in 11 serum samples. SCFAs
were separated on an ACE C18-AR column
Target compound

Concentration range
LC-QQQ-MS

Concentration range
LC-HRAM-MS

Agreement (%)

ng mL−1

nM

ng mL−1

nM

Acetic acid
Propionic acid

3170–12,782
360–1136

52,788–212,849
4860–15,335

3100–13,015
350–1156

51,622–216,729
4725–15,605

86.4–109
93.7–103

Isobutyric acid
Butyric acid

90–1241
122–1247

1021–14,085
1385–14,153

100–1211
124–1247

1135–13,745
1407–14,153

90–105
93.9–109

Isovaleric acid
Valeric acid

23.5–3992
20–100

230–39,086
196–979

23.5–3932
21–106

230–38,499
206–1038

92.7–110
91.5–110

4-Methylvaleric acid
Hexanoic acid

3.8–12
30–391

33–103
258–3366

3.7–14
27–385

31.8–120.5
232–3314

71.4–108
95.7–111
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the range 100–200 ng/mL which are at least an order of
magnitude higher than reported here [5].
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Precision, trueness, and accuracy
Intra- and inter-day variations were determined by analysing eight
different concentrations of calibration standards for six replicates in
a single day (intra-day) and one replicate for six consecutive days
(inter-day) to evaluate the precision (% CV) and trueness (% bias)
of the developed analytical method. The CV ranged from 0.34 to
12.58% and the bias for both intra-day and inter-day studies was
within ± 20% with the exception of propionic acid at
0.25 μg mL−1, where the % bias was 23.29% (Table S3).
Retention time repeatability for each analyte was determined by calculating the %RSD from the obtained retention
time after 12 injections. The %RSDs were less than 0.3% and
as low as 0.02%. Specifically, the %RSDs for retention time
repeatability were 0.29, 0.20, 0.04, 0.06, 0.04, 0.03, 0.05, and
0.02 for acetic acid, propionic acid, isobutyric acid, butyric
acid, isovaleric acid, valeric acid, 4-methyl valeric acid, and
hexanoic acid, respectively.
The accuracy of the method was determined by recovery
study. The recovery of the SCFAs in serum ranged from 93.97
to 113.81% in this study and over the three concentration
ranges tested (Table S4) and compared very favourably with
recent methods for analysis of SCFAs in serum by LC-MS.
Song et al. (2019) reported recoveries ranging between 82 and
116% [13], and Wei et al. (2020) reported recoveries of between 80 and 120% [11] for the determination of SCFA in
mouse serum, and using LC-MS.
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